August 2, 2012
Nuclea Raises $5M In Latest Funding Round
Nuclea Biotechnologies Inc., which has operations in Worcester, announced that it has closed its first Series C funding round, raising $5 million.
The funds will be used to support Nuclea's continued regulatory efforts in the development of its fatty acid synthase (FAS) assays, including clinical trials and new hires.
Nuclea has raised $35.9 million since it launched in 2005. The Pittsfield-based company has developed and is commercializing 11 diagnostic tests for colon, breast, leukemia, lung and prostate cancer. It is pursuing molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries.
WBJ Web Partners
Most Recent
Most Recent
0 Comments